

channels in malaria parasite nutrient acquisition. *Mol Pharmacol.* 2012 Sep 4; Epub ahead of print. [PMID 22949525]

2. Desai SA. Ion and nutrient uptake by malaria parasite-infected erythrocytes. *Cell Microbiol.* 2012 Jul;14(7):1003–9. [PMID 22432505]

3. Nguitragool W, et al. Malaria parasite clag3 genes determine channel-mediated nutrient uptake by infected red blood cells. *Cell.* 2011 May 27;145(5):665–77. [PMID 21620134]

4. Pillai AD, et al. A cell-based high-throughput screen validates the plasmodial surface anion channel as an antimalarial target. *Mol Pharmacol.* 2010 May;77(5):724–33. [PMID 20101003]

Intellectual Property: HHS Reference No. E–145–2011/0—International PCT Patent Application No. PCT/US12/33072 filed 11 Apr 2012.

Related Technology: HHS Reference No. E–202–2008/0—Patent family filed in the U.S., Europe, Brazil, India, and China.

Licensing Contact: Kevin W. Chang, Ph.D.; 301–435–5018; changke@mail.nih.gov.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein. For collaboration opportunities, please contact Dana Hsu at dhsu@niaid.nih.gov or 301–451–3521.

Fluorescent Magnesium Indicators

Description of Technology: A non-invasive approach in which Magnesium (Mg²⁺) ion levels can be measured in real-time. Mg²⁺ is essential to many physio-chemical processes and plays a central role in the biochemistry of all cells. Many epidemiological studies have established close association between plasma magnesium levels and various diseases including cardiovascular disease and hypertension. However, methods and tools to selectively measure cellular magnesium levels in the body with accuracy and reliability are still lacking in the market today. The present invention provides novel fluorescent indicators (carboxy-quinolizones) that are selective for Mg²⁺ and can be easily detected using fluorescence spectroscopy.

Current approaches used to measure intracellular magnesium in the body generally involve magnetic resonance spectroscopy, which is extremely expensive and subject to very poor accuracy. Unlike these other methods, the fluorescence indicators of this

invention provide a more accurate way to measure intracellular and extracellular Mg²⁺ levels in a wide variety of biological settings and have potential to be developed into diagnostic reagents.

Potential Commercial Applications:

- Tool for measuring intracellular and extracellular magnesium levels.
- Diagnostic reagent for measuring magnesium levels in a human or animal.

Competitive Advantages:

- Increased accuracy compared to what is available on the market.

- Detection is noninvasive.
- Ease of use.

Development Stage:

- Early-stage.
- In vitro data available.

Inventors: Robert E. London, Pieter Otten, Louis A. Levy (all of NIEHS).

Publications:

1. Raju B, et al. A fluorescent indicator for measuring cytosolic free magnesium. *Am J Physiol.* 1989 Mar;256(3 Pt 1):C540–8. [PMID 2923192]

2. Otten PA, et al. 4-Oxo-4H-quinolizine-3-carboxylic acids as Mg²⁺-selective, fluorescent indicators. *Bioconjugate Chem.* 2001 Mar–Apr;12(2):203–12. [PMID 11312681]

Intellectual Property: HHS Reference No. E–067–2000/0 — U.S. Patent No. 6,706,528 issued 16 Mar 2004.

Licensing Contact: Suryanarayana Vepa, Ph.D., J.D.; 301–435–5020; vepas@mail.nih.gov.

Collaborative Research Opportunity:

The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the fluorescent magnesium indicators. For collaboration opportunities, please contact Elizabeth M. Denholm, Ph.D. at denholme@niehs.nih.gov.

Dated October 18, 2012.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2012–26095 Filed 10–22–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Peer Review of SCORE Grant Applications.

Date: November 15–16, 2012.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: DoubleTree by Hilton Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Saraswathy Seetharam, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3An12C, Bethesda, MD 20892, 301–594–2763, seetharams@nigms.nih.gov.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; NIGMS Predoctoral T32 Review SEP.

Date: November 16, 2012.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Room 3An18K, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Brian R. Pike, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3An18, Bethesda, MD 20892, 301–594–3907, pikebr@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: October 17, 2012.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–26012 Filed 10–22–12; 8:45 am]

BILLING CODE 4140–01–P